Press Releases

Home / Investor Relations / Press Releases

Language

Category

Year

2020-07-17 08:01 Boule Diagnostics AB (publ) Interim report January–June 2020 Regulatory

Continued business development in the shadow of COVID-19 The Board of Boule Diagnostics AB decided to withdraw the previously communicated dividend proposal. The Board’s decision was made in light of the increased uncertainty of the market outlook following...

2020-07-10 08:31 Boule Diagnostics publishes the interim report Q2 2020 on July 17, 2020 at 08.00 CET

Boule Diagnostics AB will bring the publishing of the interim report for the period January–June 2020 forward to 08:00, Friday, July 17th, 2020. The previously communicated publishing date was August 17th. The interim report will be accessible at www.boule.com...

2020-07-09 22:16 Boule Diagnostics AB writes-off the asset shares in Associate Regulatory

Following an impairment test of the associated company biosurfit, Boule Diagnostics have decided to write-off the entire shareholding in the associated company, which will have a negative non-cash effect on profit of SEK 36.6 million in the second quarter...

2020-05-07 20:16 Bulletin from Annual General Meeting in Boule Diagnostics AB on May 7, 2020

The Annual General Meeting 2020 (the ”AGM”) decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2019. Furthermore, it was decided that no dividend will be distributed for the financial...

2020-05-07 15:01 Boule Diagnostics AB (publ) Interim report January–March 2020 Regulatory

Stable start to the year Closeout letter received from the FDA On February 28, 2020, Boule received a closeout letter from the US FDA (Food and Drug Administration) which described that the authority had completed their evaluation of the company’s...

2020-05-05 15:01 Boule Diagnostics – Presentation of the interim report Q1 2020

Boule Diagnostics AB will publish the interim report for the period January–March 2020 at 15:00, Thursday, May 7th, 2020. Following the publication, Boule will hold a conference call at 16:00 for media and investors. CFO and acting CEO Christina...

2020-04-16 15:01 Boule Diagnostics publishes the annual report for 2019 Regulatory

Boule Diagnostics AB has published the full annual report for the fiscal year 2019 in Swedish at www.boule.com. The annual report is available in Swedish below and printed copies of the Swedish version will be available to shareholders upon request by...

2020-04-02 10:11 Boule Diagnostics withdraws the proposed dividend

The Board of Boule Diagnostics AB has decided to withdraw the previously communicated dividend proposal of SEK 0.60 per share, a total of SEK 11.6 million. The Board proposes instead that no dividend will be paid. The Board’s decision was made in light...

2020-02-29 15:21 Boule Diagnostics receives warning letter closure Regulatory

Boule Medical (a Boule Diagnostics subsidiary) has received correspondence on February 28, 2020 stating that the Food and Drug Administration (FDA) has completed their evaluation of the firm’s corrective actions in response to the Warning Letter dated...

2020-02-07 15:01 Boule Diagnostics AB (publ) Year-end report January-December 2019 Regulatory

New record in number of instruments sold, continued strong growth and improved profitability Jesper Söderqvist appointed CEO Jesper Söderqvist has been appointed new CEO and Group President with effect no later than May 11, 2020. Jesper has 15 years...

2020-02-05 15:00 Boule Diagnostics – Presentation of the year-end report 2019

Boule Diagnostics AB will publish the year-end report for the period January-December 2019 at 15:00, Friday, February 7th, 2020. Following the publication, Boule will hold a conference call at 16:00 for media and investors. CFO and acting CEO Christina...

2020-01-27 09:00 Boule Diagnostics – Field corrective action

During recent routine internal quality processes, Boule identified a potential risk of malfunction that can occur during certain specific conditions with the Autoloader version of its hematology analyzers. In accordance with the company’s improved Quality...

2019-12-13 16:16 Christina Rubenhag appointed acting CEO and Peter Ehrenheim will assume the role as working Chairman of the Board of Boule Diagnostics

The Board of Directors of Boule Diagnostics AB has appointed Christina Rubenhag acting CEO and Group President as of January 19, 2020, the date on which Fredrik Dalborg leaves the position as CEO and Group President. Christina will maintain the position...

2019-11-11 18:01 Jesper Söderqvist appointed new CEO of Boule Diagnostics Regulatory

The Board of Directors of Boule Diagnostics AB has appointed Jesper Söderqvist as the new CEO and Group President with effect no later than May 11, 2020. Jesper has 15 years of experience of senior management positions in med-tech companies and a broad...

2019-10-30 15:01 Boule Diagnostics AB (publ) Interim report January–September 2019 Regulatory

Continued strong growth and significantly improved margins Fredrik Dalborg leaves the position as CEO of Boule Fredrik Dalborg, CEO and Group President of Boule Diagnostics, has as previously communicated decided to leave the company and continue his...

2019-10-28 15:01 Boule Diagnostics – Q3 2019 presentation

Boule Diagnostics AB will publish the interim report for the period January – September 2019 at 15:00, Wednesday October 30, 2019. Following the publication, Boule will hold a conference call at 16:00 for media and investors. CEO Fredrik Dalborg...

2019-10-21 15:01 Boule Diagnostics – Nomination Committee for the 2020 Annual General Meeting

The Annual General Meeting, (”AGM”), 2019 of Boule Diagnostics AB (publ), (”Boule”), decided that a Nomination Committee based on the ownership structure as per September 30, 2019, will be appointed to propose for the AGM of 2020 the following...

2019-08-14 15:04 Boule Diagnostics AB (publ) Interim report January–June 2019 Regulatory

The trend of strong growth in sales continues In connection with changes in the distributor structure in Russia, a credit risk has been identified. Therefore, Boule has made an increase of the bad debt reserve of SEK 5.9 million. Fredrik Dalborg leaves...

2019-08-12 15:00 Boule Diagnostics – Q2 2019 presentation

Boule Diagnostics AB will publish the interim report for the period January – June 2019 at 15:00, Wednesday August 14, 2019. Following the publication, Boule will hold a conference call at 16:00 for media and investors. CEO Fredrik Dalborg and CFO Christina...

2019-07-22 08:01 Fredrik Dalborg leaves the position as CEO of Boule Diagnostics AB Regulatory

Fredrik Dalborg, CEO and Group President of Boule Diagnostics, has decided to leave the company and continue his career with new assignments outside the Group in another Swedish medical technology company. Fredrik will remain in his role during his period...

Previous Next